Details:

Alternative Title:
Open Forum Infect Dis
Personal Author:
Acosta, Anna M ; Mathis, Adria L ; Budnitz, Daniel S ; Geller, Andrew I ; Chai, Shua J ; ... More +
Acosta, Anna M ; Mathis, Adria L ; Budnitz, Daniel S ; Geller, Andrew I ; Chai, Shua J ; Alden, Nisha B ; Meek, James ; Anderson, Evan J ; Ryan, Patricia ; Kim, Sue ; Como-Sabetti, Kathryn ; Torres, Salina ; Dufort, Elizabeth ; Bennett, Nancy M ; Billing, Laurie M ; Sutton, Melissa ; Keipp Talbot, H ; George, Andrea ; Pham, Huong ; Hall, Aron J ; Fry, Alicia ; Garg, Shikha ; Kim, Lindsay Less -
Description:
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
Subjects:
[+]
COVID-19 Hospitalization
Source:
Open Forum Infect Dis. 2020; 7(11)
Pubmed ID:
33274249
Pubmed Central ID:
PMC7686662
Document Type:
Journal Article
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:0deebca69fa556da226d68e2c8f4ef657d81c9eda898187873f9764c5ae0f2dc
Download URL:
https://stacks.cdc.gov/view/cdc/98895/cdc_98895_DS1.pdf
File Type:

Supporting Files

• 	ofaa528.nxml	xml
  	ofaa528_fig1.gif	gif
  	ofaa528_fig1.jpg	jpeg
  	ofaa528_suppl_supplementary_figure_1.png	png
  	ofaa528_suppl_supplementary_figure_2.png	png
  	ofaa528_suppl_supplementary_materials_1.docx	docx

More +